Advanced breast cancer: Benefits of Trastuzumab (Herceptin) outweigh the risk of harm

June 11, 2014

In women with advanced (or metastatic) breast cancer, treatment with the breast cancer drug Trastuzumab (Herceptin) is associated with prolonged survival but also increases the risk of developing heart problems, a new systematic review shows. However, the review, published in The Cochrane Library, concludes that more women benefit from use of Trastuzumab than are harmed.

The review focuses on treatment for with advanced stage who have tested HER2- positive. About 1 in 5 women with breast cancer are HER2-positive. HER2 is a protein on the surface of breast cells called human epidermal growth factor receptor 2. It encourages to grow and divide. The prognosis for HER2-positive patients is usually worse because the high levels of HER2 on their tumour cells make their cancer more aggressive.

The antibody-based drug Trastuzumab is designed to target these specific types of tumours. It has been recommended for treating women who have HER2-positive since 1998 in the US and 2002 in the UK.

The authors reviewed data from seven trials involving a total of 1,497 HER2-positive women with metastatic breast cancer, meaning their cancer could be treated but not cured. The women were given Trastuzumab in combination with other drugs, either as a first-line treatment or later therapy, when their cancer had progressed.

Overall survival rates two years after starting the trials were higher for women who were given Trastuzumab than for those on regimens that did not include the drug. Women on Trastuzumab also gained another two to eleven months without further progression of their cancers. The drug was most effective when it was used as a first-line treatment or in combination with the chemotherapy drug class called taxanes.

"This review suggests that, for women with advanced breast cancer, Trastuzumab (Herceptin) has been linked to significant life expectancy gains," said Lorenzo Moja, one of the authors of the review, based at the Department of Biomedical Sciences for Health at the University of Milan in Milan, Italy. "We found that women survived longer and their cancer did not progress as quickly when they received Trastuzumab (Herceptin)."

However, the drug led to an increased risk of heart failure. With standard therapies, the equivalent of 300 in every 1,000 women survived at two years and only 10 developed heart problems. When Trastuzumab (Herceptin®) was added, 373 survived, but 35 developed heart problems that required immediate discontinuation of Trastuzumab. These cardiac dysfunctions were usually reversible after treatment stopped.

The review highlighted one particular drug combination associated with a higher risk of . "Some of the earlier trials combined Trastuzumab (Herceptin®) with a class of drugs called anthracyclines," said Roberto D'Amico, director of the Italian Cochrane Centre, University of Modena and Reggio Emilia, Italy and co-author of the review. "This combination is not recommended in patients with ."

Explore further: Balancing trastuzumab's survival benefits and heart risks for women with breast cancer

More information: Balduzzi S., Mantarro S., Guarneri V., Tagliabue L., Pistotti V., Moja L., D'Amico R., Trastuzumab containing regimens for metastatic breast cancer. Cochrane Database of Systematic Reviews 2014, Issue 8. Art. No.:CD006242. DOI: 10.1002/14651858.CD006242.pub2

Related Stories

Balancing trastuzumab's survival benefits and heart risks for women with breast cancer

April 17, 2012
Adding trastuzumab (trade name Herceptin) to the treatment offered to women who have HER2-positive breast cancer, significantly increases the chance of life being prolonged, and reduces the chance of tumours reappearing once ...

Study finds risk of recurrence low in smallest HER2+ breast cancer tumors

June 2, 2014
Patients with specific HER2+ breast cancer tumors had a low risk of the cancer recurring five years after diagnosis, even without chemotherapy or treatment with a common antibody, according to a Kaiser Permanente study published ...

Experts issue treatment guidelines for aggressive form of breast cancer

May 5, 2014
(HealthDay)—Two sets of guidelines for treating patients with an aggressive form of breast cancer have been released by the American Society of Clinical Oncology (ASCO).

Trastuzumab emtansine: Indication of major added benefit in one subpopulation

April 7, 2014
The antibody-drug conjugate trastuzumab emtansine (trade name: Kadcyla) has been approved since November 2013 for the treatment of patients with unresectable, locally advanced or metastatic breast cancer that is HER2-positive, ...

Enhancing the effectiveness of a breast cancer treatment

February 13, 2012
Breast cancers expressing the protein HER2 have a particularly poor prognosis. Treatment with trastuzumab (Herceptin) benefits some patients with HER2-positive breast cancer, but it is not as effective as had been hoped. ...

Many breast cancer patients don't get treatment for heart problems

June 3, 2014
Only a third of older breast cancer patients saw a cardiologist within 90 days of developing heart problems, in a study presented at the American Heart Association's Quality of Care and Outcomes Research 2014 Scientific Sessions.

Recommended for you

Cancer-death button gets jammed by gut bacterium

July 27, 2017
Researchers at Michigan Medicine and in China showed that a type of bacterium is associated with the recurrence of colorectal cancer and poor outcomes. They found that Fusobacterium nucleatum in the gut can stop chemotherapy ...

Researchers release first draft of a genome-wide cancer 'dependency map'

July 27, 2017
In one of the largest efforts to build a comprehensive catalog of genetic vulnerabilities in cancer, researchers from the Broad Institute of MIT and Harvard and Dana-Farber Cancer Institute have identified more than 760 genes ...

Long-sought mechanism of metastasis is discovered in pancreatic cancer

July 27, 2017
Cells, just like people, have memories. They retain molecular markers that at the beginning of their existence helped guide their development. Cells that become cancerous may be making use of these early memories to power ...

Blocking the back-door that cancer cells use to escape death by radiotherapy

July 27, 2017
A natural healing mechanism of the body may be reducing the efficiency of radiotherapy in breast cancer patients, according to a new study.

Manmade peptides reduce breast cancer's spread

July 27, 2017
Manmade peptides that directly disrupt the inner workings of a gene known to support cancer's spread significantly reduce metastasis in a mouse model of breast cancer, scientists say.

Glowing tumor technology helps surgeons remove hidden cancer cells

July 27, 2017
Surgeons were able to identify and remove a greater number of cancerous nodules from lung cancer patients when combining intraoperative molecular imaging (IMI) - through the use of a contrast agent that makes tumor cells ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.